芬兰前列腺癌筛查随机研究20年随访的医疗成本分析
基于芬兰前列腺癌筛查随机研究(FinRSPC)20年随访的登记数据,分析80149名男性的公共医疗成本。结果显示筛查组前列腺癌相关成本约低10%,但全因成本差异较小且不显著;筛查对总体成本影响不大,20年随访期尚不足以提供确定性证据。
要点
- 筛查组前列腺癌相关平均成本约低10%,但全因成本差异不显著。
- 死于前列腺癌者筛查组全因成本约高10%,差异无统计学意义。
- 总体累积成本筛查组略高或略低,取决于是否排除极端值,无重大成本影响。
核心结论
- 筛查对医疗成本无重大影响,但20年随访期不足以提供确定性证据。
- 需更长期随访才能更好了解大规模前列腺癌筛查的成本或节省。
研究设计与样本
- 基于芬兰前列腺癌筛查随机研究(FinRSPC)的登记数据,纳入80149名男性,随访20年。
- 获取处方药、住院和门诊的个体级登记数据,估算公共医疗成本并比较两组。
主要发现
- 20年内诊断为前列腺癌的男性中,筛查组前列腺癌相关平均成本约低10%。
- 这些男性的全因平均成本筛查组也较低,但差异较小且无统计学显著性。
- 死于前列腺癌的男性中,筛查组全因平均成本约高10%,差异无统计学意义。
- 纳入所有观察时累积成本对照组略高,排除极端值后筛查组略高。
临床怎么用
- 筛查决策时可参考前列腺癌相关成本约低10%的估计,但需注意全因成本差异不显著。
- 当前证据尚不支持将成本作为大规模筛查的主要决策依据。
局限性
- 20年随访期不足以提供确定性证据。
- 极端值对累积成本比较方向有影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Few empirical analyses of the impact of organised prostate cancer (PCa) screening on healthcare costs exist, despite cost-related information often being considered as a prerequisite to informed screening decisions. Therefore, we estimate the differences in register-based costs of publicly funded healthcare in the two arms of the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20 years. METHODS: We obtained individual-level register data on prescription medications, as well as inpatient and outpatient care, to estimate healthcare costs for 80,149 men during the first 20 years of the FinRSPC. We compared healthcare costs for the men in each trial arm and performed statistical analysis. RESULTS: For all men diagnosed with PCa during the 20-year observation period, mean PCa-related costs appeared to be around 10% lower in the screening arm (SA). Mean all-cause healthcare costs for these men were also lower in the SA, but differences were smaller than for PCa-related costs alone, and no longer statistically significant. For men dying from PCa, although the difference was not statistically significant, mean all-cause healthcare costs were around 10% higher. When analysis included all observations, cumulative costs were slightly higher in the CA; however, after excluding extreme values, cumulative costs were slightly higher in the SA. CONCLUSIONS: No major cost impacts due to screening were apparent, but the FinRSPC's 20-year follow-up period is too short to provide definitive evidence at this stage. Longer term follow-up will be required to be better informed about the costs of, or savings from, introducing mass PCa screening.
引用
- Booth N, Rissanen P, Tammela TLJ, et al. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. Eur J Cancer. 2018. PMID: 29501976. doi:10.1016/j.ejca.2018.01.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。